References
- 1. P. J. Thornalley, The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life, Biochem. J. 269 (1990) 1–11.
- 2. M. Sousa Silva, R. A. Gomes, A. E. N. Ferreira, A. P. Freire and C. Cordeiro, The glyoxalase pathway: the first hundred years… and beyond, Biochem. J. 453 (2013) 1–15; https://doi.org/10.1042/bj2012174310.1042/BJ20121743
- 3. A. Rulli, L. Carli, R. Romani, T. Baroni, E. Giovannini, G. Rosi and V. Talesa, Expression of glyoxalase I and II in normal and breast cancer tissues, Breast Cancer Res. Treat. 66 (2001) 67–72; https://doi.org/10.1023/a:101063291912910.1023/A:1010632919129
- 4. E. Mearini, R. Romani, L. Mearini, C. Antognelli, A. Zucchi, T. Baroni, M. Porena and V. N. Talesa, Differing expression of enzymes of the glyoxalase system in superficial and invasive bladder carcinomas, Eur. J. Cancer38 (2002) 1946–1950; https://doi.org/10.1016/S0959-8049(02)00236-810.1016/S0959-8049(02)00236-8
- 5. P. J. Thornalley, The glyoxalase system in health and disease, Mol. Aspects Med.14 (1993) 287–371; https://doi.org/10.1016/0098-2997(93)90002-U10.1016/0098-2997(93)90002-U
- 6. Q. Al-Balas, M. Hassan, B. Al-Oudat, H. Alzoubi, N. Mhaidat and A. Almaaytah, Generation of the first structure-based pharmacophore model containing a selective “zinc binding group” feature to identify potential glyoxalase-I inhibitors, Molecules17 (2012) 13740–13758; https://doi.org/10.3390/molecules17121374010.3390/molecules171213740626817123174893
- 7. A. N. Al-Shar’i, M. Hassan, Q. Al-Balas and A. Almaaytah, Identification of possible glyoxalase II inhibitors as anticancer agents by a customized 3D structure-based pharmacophore model, Jordan J. Pharm. Sci. 8 (2015) 83–103.10.12816/0025734
- 8. A. D. Cameron, B. Olin, M. Ridderström, B. Mannervik and T. A. Jones, Crystal structure of human glyoxalase I - evidence for gene duplication and 3D domain swapping, EMBO J. 16 (1997) 3386–3395; https://doi.org/10.1093/emboj/16.12.338610.1093/emboj/16.12.338611699649218781
- 9. Q. A. Al-Balas, M. A. Hassan, N. A. Al-Shar’i, N. M. Mhaidat, A. M. Almaaytah, F. M. Al-Mahasneh, and I. H. Isawi, Novel glyoxalase-I inhibitors possessing a “zinc-binding feature” as potential anti-cancer agents, Drug Des. Dev. Ther.10 (2016) 2623–2629; https://doi.org/10.2147/DDDT.S11099710.2147/DDDT.S110997499325727574401
- 10. Q. A. Al-Balas, A. M. Hassan, G. A. Al Jabal, N. A. Al-Shar’i, A. M. Almaaytah and T. El-Elimat, Novel thiazole carboxylic acid derivatives possessing a “zinc binding feature” as potential human glyoxalase-I inhibitors, Lett. Drug Des. Discov.14 (2017) 1324–1334; https://doi.org/10.2174/157018081466617030612095410.2174/1570180814666170306120954
- 11. Q. A. Al-Balas, M. A. Hassan, N. A. Al-Shar’i, T. El-Elimat and A. M. Almaaytah, Computational and experimental exploration of the structure–activity relationships of flavonoids as potent glyoxalase-I inhibitors, Drug Dev. Res. 79 (2018) 58–69; https://doi.org/10.1002/ddr.2142110.1002/ddr.2142129285772
- 12. Q. Al-Balas, N. Al-Shar’i, K. Banisalman, M. Hassan, G. A. Jabal and A. Almaaytah, Design, synthesis and biological evaluation of potential novel zinc binders targeting human glyoxalase-I; A validated target for cancer treatment, Jordan J. Pharm. Sci. 11 (2018) 25–37.
- 13. Q. A. Al-Balas, M. A. Hassan, N. A. Al-Shar’i, G. A. Al Jabal and A. M. Almaaytah, Recent advances in glyoxalase-I inhibition, Mini-Rev. Med. Chem.19 (2019) 281–291; https://doi.org/10.2174/138955751866618100914123110.2174/138955751866618100914123130306863
- 14. N. A. Al-Shar’i, Q. A. Al-Balas, R. A. Al-Waqfi, M. A. Hassan, A. E. Alkhalifa and N. M. Ayoub, Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based polypharmacophore modelling and molecular docking, J. Comput. Aid. Mol. Des. 33 (2019) 799–815; https://doi.org/10.1007/s10822-019-00226-810.1007/s10822-019-00226-831630312
- 15. N. A. Al-Shar’i, E. K. Al-Rousan, L. I. Fakhouri, Q. A. Al-Balas and M. A. Hassan, Discovery of a nanomolar glyoxalase-I inhibitor using integrated ligand-based pharmacophore modeling and molecular docking, Med. Chem. Res. 29 (2020) 356–376; https://doi.org/10.1007/s00044-019-02486-310.1007/s00044-019-02486-3
- 16. B. R. Brooks, C. L. Brooks, A. D. MacKerell, L. Nilsson, R. J. Petrella, B. Roux, Y. Won, G. Archontis, C. Bartels, S. Boresch, A. Caflisch, L. Caves, Q. Cui, A. R. Dinner, M. Feig, S. Fischer, J. Gao, M. Hodoscek, W. Im, K. Kuczera, T. Lazaridis, J. Ma, V. Ovchinnikov, E. Paci, R. W. Pastor, C. B. Post, J. Z. Pu, M. Schaefer, B. Tidor, R. M. Venable, H. L. Woodcock, X. Wu, W. Yang, D. M. York and M. Karplus, CHARMM: The biomolecular simulation program, J. Comput. Chem. 30 (2009) 1545–1614; https://doi.org/10.1002/jcc.2128710.1002/jcc.21287281066119444816
- 17. M. S. Lee, M. Feig, F. R. Salsbury and C. L. Brooks, New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations, J. Comput. Chem. 24 (2003) 1348–1356; https://doi.org/doi:10.1002/jcc.1027210.1002/jcc.1027212827676
- 18. P. Mark and L. Nilsson, Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K, J. Phys. Chem. A105 (2001) 9954–9960; https://doi.org/10.1021/jp003020w10.1021/jp003020w
- 19. I. Štich, R. Car, M. Parrinell and S. Baroni, Conjugate gradient minimization of the energy functional: A new method for electronic structure calculation, Phys. Rev. B39 (1989) 4997–5004; https://doi.org/10.1103/PhysRevB.39.499710.1103/PhysRevB.39.4997
- 20. G. Wu, D. H. Robertson, C. L. Brooks and M. Vieth, Detailed analysis of grid-based molecular docking: A case study of CDOCKER—A CHARMm-based MD docking algorithm, J. Comput. Chem. 24 (2003) 1549–1562; https://doi.org/10.1002/jcc.1030610.1002/jcc.1030612925999
- 21. R. Takasawa, H. Akahane, H. Tanaka, N. Shimada, T. Yamamoto, H. Uchida-Maruki, M. Sai, A. Yoshimori and S.-i. Tanuma, Piceatannol, a natural trans-stilbene compound, inhibits human glyoxalase I, Bioorg. Med. Chem. Lett.27 (2017) 1169–1174; https://doi.org/10.1016/j.bmcl.2017.01.07010.1016/j.bmcl.2017.01.07028169168
- 22. A. Z. Simić, T. Ž. Verbić, M. N. Sentić, M. P. Vojić, I. O. Juranić and D. D. Manojlović, Study of ellagic acid electro-oxidation mechanism, Monatsh. Chem. Chem. Mon. 144 (2013) 121–128; https://doi.org/10.1007/s00706-012-0856-810.1007/s00706-012-0856-8
- 23. Z. Marković, D. Milenković, J. Đorović, J. M. Dimitrić Marković, B. Lučić and D. Amić, A DFT and PM6 study of free radical scavenging activity of ellagic acid, Monatsh. Chem. Chem. Mon.144 (2013) 803–812; https://doi.org/10.1007/s00706-013-0949-z10.1007/s00706-013-0949-z
- 24. Y. Yao, G. Lin, Y. Xie, P. Ma, G. Li, Q. Meng and T. Wu, Preformulation studies of myricetin: a natural antioxidant flavonoid, Pharmazie69 (2014) 19–26.
- 25. R. S. Mulliken, Electronic population analysis on LCAO–MO molecular wave functions. I, J. Chem. Phys. 23 (1955) 1833–1840; https://doi.org/10.1063/1.174058810.1063/1.1740588
- 26. F. L. Hirshfeld, Bonded-atom fragments for describing molecular charge densities, Theor. Chim. Acta44 (1977) 129–138; https://doi.org/10.1007/bf0054909610.1007/BF00549096
- 27. H. F. P. Martins, J. P. Leal, M. T. Fernandez, V. H. C. Lopes and M. N. D. S. Cordeiro, Toward the prediction of the activity of antioxidants: experimental and theoretical study of the gas-phase acidities of flavonoids, J. Am. Soc. Mass Spectrom. 15 (2004) 848–861; https://doi.org/10.1016/j.jasms.2004.02.00710.1016/j.jasms.2004.02.007
- 28. G. Günther, E. Berríos, N. Pizarro, K. Valdés, G. Montero, F. Arriagada and J. Morales, Flavonoids in microheterogeneous media, relationship between their relative location and their reactivity towards singlet oxygen, PLoS ONE10 (2015) e0129749; https://doi.org/10.1371/journal.pone.012974910.1371/journal.pone.0129749
- 29. B. Delley, An all-electron numerical method for solving the local density functional for polyatomic molecules, J. Chem. Phys.92 (1990) 508–517; https://doi.org/10.1063/1.45845210.1063/1.458452
- 30. T. Lengauer and M. Rarey, Computational methods for biomolecular docking, Curr. Opin. Struct. Biol.6 (1996) 402–406; https://doi.org/10.1016/S0959-440X(96)80061-310.1016/S0959-440X(96)80061-3
- 31. P. Ferrara, H. Gohlke, D. J. Price, G. Klebe and C. L. Brooks, Assessing Scoring functions for protein-ligand interactions, J. Med. Chem.47 (2004) 3032–3047; https://doi.org/10.1021/jm030489h10.1021/jm030489h15163185
- 32. S. Genheden and U. Ryde, The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities, Expert Opin. Drug Discov.10 (2015) 449–461; https://doi.org/10.1517/17460441.2015.103293610.1517/17460441.2015.1032936448760625835573
- 33. S. Matić, M. Jadrijević-Mladar Takač, M. Barbarić, B. Lučić, K. Gall Trošelj and V. Stepanić, The influence of in vivo metabolic modifications on ADMET properties of green tea catechins – In silico analysis, J. Pharm. Sci. 107 (2018) 2957–2964; https://doi.org/10.1016/j.xphs.2018.07.02610.1016/j.xphs.2018.07.02630077700
- 34. N. J. Cox, Speaking stata: Correlation with confidence, or Fisher’s z revisited, Stata J. 8 (2008) 413–439; https://ageconsearch.umn.edu/record/122603
- 35. D. A. Vattem and K. Shetty, Biological functionality of ellagic acid: a review, J. Food Biochem. 29 (2005) 234–266; https://doi.org/10.1111/j.1745-4514.2005.00031.x10.1111/j.1745-4514.2005.00031.x
- 36. J. M. Landete, Ellagitannins, ellagic acid and their derived metabolites: A review about source, metabolism, functions and health, Food Res. Int.44 (2011) 1150–1160; https://doi.org/10.1016/j.foodres.2011.04.02710.1016/j.foodres.2011.04.027